COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Biological Evaluation of Dietary Supplement Liposomal Glutathione

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01967667
Recruitment Status : Suspended (lack of funding)
First Posted : October 23, 2013
Last Update Posted : March 24, 2020
Information provided by (Responsible Party):
MPRC, University of Maryland, Baltimore

Brief Summary:
Low levels of antioxidant molecules such as glutathione have been found in people with a diagnosis of schizophrenia. However, oral glutathione is not well absorbed because the compound is mostly broken down in the gastrointestinal system. Liposomes are tiny droplets of oil particles that encapsulate and protect the glutathione. In this study we will evaluate a liposomal formulation of glutathione for tolerability and to examine if this formulation serves the function of increasing glutathione in the brain and body.

Condition or disease Intervention/treatment Phase
Schizophrenia Dietary Supplement: Liposomal glutathione Dietary Supplement: Placebo Not Applicable

Detailed Description:

Additional information about this dietary supplement:

  • Glutathione is an antioxidant naturally produced in our body. Glutathione protects the brain and other organs from oxidative stress.
  • Low glutathione is associated with high oxidative stress, which has been linked to aging and many illnesses. Schizophrenia is a mental illness that doctors still do not fully understand. Individuals with schizophrenia often have low levels of glutathione.
  • Glutathione can be supplied through dietary supplement. However, if taken plainly, it easily breaks down in our gut.
  • Scientists have now found a way to wrap glutathione in tiny drops of oil particles called liposomes. That way, the gut cannot break it down so it is absorbed into our body. Once inside the body, our cells can take in the liposomes and use the glutathione to reduce oxidative stress.
  • Liposome-wrapped glutathione is not a drug or medicine.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: Biological Evaluation of Dietary Supplement Liposomal Glutathione
Study Start Date : April 2014
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Glutathione

Arm Intervention/treatment
Experimental: Liposomal glutathione
dose steps
Dietary Supplement: Liposomal glutathione
Escalating dose steps
Other Name: ReadiSorb glutathione

Placebo Comparator: Placebo
dose steps
Dietary Supplement: Placebo
escalating dose steps
Other Name: Readisorb solution without glutathione

Primary Outcome Measures :
  1. Glutathione levels [ Time Frame: Baseline and 3 weeks ]
    Change of glutathione levels from baseline to following 3 weeks of treatment.

Secondary Outcome Measures :
  1. oxidative stress biomarker [ Time Frame: baseline and 3 weeks ]
    blood levels of lipid peroxidation

  2. inflammatory marker [ Time Frame: baseline and 3 weeks ]
    Blood levels of cytokines as biomarkers of inflammation

Other Outcome Measures:
  1. BPRS [ Time Frame: Baseline and 3 weeks ]
    Change in brief psychiatric rating scale scores from baseline to end of treatment phase and end of placebo phase.

  2. Adverse events [ Time Frame: Baseline and 3 weeks ]
    side-effects checklist

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age range: 18-60
  • DSM diagnosis of schizophrenia spectrum disorder, including schizophrenia, schizoaffective disorder, and schizophreniform disorder
  • Ability to give written informed consent (Evaluation to Sign Consent score 10 or greater)
  • Clinically stable with no change in antipsychotic medications nor significant increase of daily dose for 2 weeks prior to enrollment
  • Low baseline blood glutathione level (GSH < 890 umol/l)

Exclusion Criteria:

  • History of major medical illness including, but not limited to, history of heart attack, stroke, TIA (transient ischemic attack)
  • History of organic brain disorders that may affect neurophysiological measurements, including seizure disorder, brain tumor, head injury with evidence of significant cognitive deterioration
  • DSM diagnosis of substance dependence within 6 months except nicotine and marijuana, or substance abuse in past month
  • Uncontrolled blood pressure (persistent systolic above 165 or diastolic above 100)
  • On medication containing cholesterol absorption inhibitor such as ezetimibe (Brand names Zetia, Ezetrol, Vytorin, and Inegy)
  • Women who have positive urine pregnancy tests
  • Women who plan to become pregnant, or are breastfeeding
  • Unable to undergo MRI scanning due to metallic devices or objects or claustrophobia
  • Already taking dietary antioxidant supplements such as n-acetylcysteine or fish oil on regular basis (more than twice a week) in the last 3 months
  • History of allergy to soy or soy products
  • Hyperlipidemia (baseline LDL > 1.5 x upper limit of normal)
  • Liver impairment (baseline AST or ALT > 2.0 x upper limit of normal)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01967667

Layout table for location information
United States, Maryland
Maryland Psychiatric Research Center
Catonsville, Maryland, United States, 21228
Sponsors and Collaborators
University of Maryland, Baltimore
Layout table for investigator information
Principal Investigator: L. Elliot Hong, MD University of Maryland, College Park

Layout table for additonal information
Responsible Party: MPRC, Professor, University of Maryland, Baltimore Identifier: NCT01967667    
Other Study ID Numbers: HP-00056458
First Posted: October 23, 2013    Key Record Dates
Last Update Posted: March 24, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders